Search research articles
Contact Us
Filters
Showing results (101-110 of 190) with videos related to
Page
of 19
Sort By:
American Journal of Clinical Oncology
|
September 23, 2009
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach
Charles D Blanke, Kari Chansky, Kathy L Christman, et al.
Journal of Surgical Oncology
|
October 23, 2008
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665
Burton L Eisenberg, Jonathan Harris, Charles D Blanke, et al.
Clinical Colorectal Cancer
|
July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database
Winson Y Cheung, Qian Shi, Michael O'Connell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)
Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Seminars in Oncology
|
October 5, 2015
The Globalization of Cooperative Groups
Manuel Valdivieso, Benjamin W Corn, Janet E Dancey, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 9, 2005
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer
Karen L Tedesco, Jordan Berlin, Charles D Blanke, et al.
Cancer
|
April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer
|
July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)
Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
Cancer
|
July 22, 2014
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)
Cornelia M Ulrich, Cathryn Rankin, Adetunji T Toriola, et al.
Investigational New Drugs
|
October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 190) with videos related to
Sort By:
Page
of 19
American Journal of Clinical Oncology
|
September 23, 2009
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach
Charles D Blanke, Kari Chansky, Kathy L Christman, et al.
Journal of Surgical Oncology
|
October 23, 2008
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665
Burton L Eisenberg, Jonathan Harris, Charles D Blanke, et al.
Clinical Colorectal Cancer
|
July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database
Winson Y Cheung, Qian Shi, Michael O'Connell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)
Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Seminars in Oncology
|
October 5, 2015
The Globalization of Cooperative Groups
Manuel Valdivieso, Benjamin W Corn, Janet E Dancey, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 9, 2005
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer
Karen L Tedesco, Jordan Berlin, Charles D Blanke, et al.
Cancer
|
April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer
|
July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)
Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
Cancer
|
July 22, 2014
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)
Cornelia M Ulrich, Cathryn Rankin, Adetunji T Toriola, et al.
Investigational New Drugs
|
October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Page
of 19